Therapeutic Use of Botulinum Neurotoxin in the Treatment of pain associated with diabetic neuropathy
AssigneeIpsen Pharma S.A.S.
InventorsChristine FAVRE, Michel AUGUET, Piere-Etienne CHABRIER DE LASSAUNIERE
Life of this patent
Estimating the term…
Abstract
The present invention relates to at least one botulinum neurotoxin for treatment or prevention of pain associated with diabetic neuropathy wherein said botulinum neurotoxin is prepared for local administration, wherein the local administration is not in the central nervous system (CNS), and wherein pain is treated at a site distant to the site of administration.
Claims14
At least one botulinum neurotoxin for treatment of pain associated with diabetic neuropathy, wherein said botulinum neurotoxin is prepared for local administration, wherein the local administration is not in the central nervous system (CNS), and wherein pain is treated at a site distant to the site of administration.
The botulinum neurotoxin according to any one of the preceding claims, prepared for local administration into a limb.
The botulinum neurotoxin according to any one of the preceding claims, prepared for local administration into a hand or a foot.
The botulinum neurotoxin according to any one of the preceding claims, prepared for administration into the palm of a hand or the sole of a foot.
The botulinum neurotoxin according to any one of the preceding claims, prepared for local administration limited to one side of the body.
The botulinum neurotoxin according to any one of the preceding claims, prepared for administration into a site that is distant from a painful site.
The botulinum neurotoxin according to any one of the preceding claims, prepared for administration no more frequently than once per month or nor more frequently than once every six weeks or no more frequently than once every 8 weeks.
The botulinum neurotoxin according to any one of the preceding claims, wherein said local administration is selected from sub-cutaneous, intra-muscular, intradermal or transdermal administration.
The botulinum neurotoxin according to any one of the preceding claims, wherein the botulinum neurotoxin is selected from botulinum neurotoxin type A, A1, A2, A3, A4, B, C, C1, D, E, F or G.
The botulinum neurotoxin according to any one of the preceding claims, wherein the botulinum neurotoxin is the botulinum toxin of type A1.
The botulinum neurotoxin according to any one of the preceding claims, prepared for administration at a dose comprised between 1 U and 1500 U.
The botulinum neurotoxin according to any one of the preceding claims, prepared for administration at a dose comprised between 100 and 500 U.
Dependencies are inferred from the claim text.